PF-Atlas › Clinical Trials › NCT05229640

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

Fibroscan · Not specified

Registry ID
NCT05229640
Phase
Not specified
Status
Withdrawn
Drug / intervention
Fibroscan
Sponsor
Dartmouth-Hitchcock Medical Center
Start
2022-03-31

About this trial

Fibroscan is evaluated in NCT05229640, a idiopathic pulmonary fibrosis study sponsored by Dartmouth-Hitchcock Medical Center. Current status: Withdrawn.

View NCT05229640 on ClinicalTrials.gov →

Explore related

All Fibroscan trialsAll IPF trials

Related trials

Fibroscan — NCT02603666FibroScan — NCT00777725
Medical disclaimer. This page summarizes public trial data for NCT05229640 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.